This article was originally published in The Gray Sheet
Executive SummaryInks deal with Merck & Co. under which it gains rights to incorporate OsteoGram software enhancements developed by Merck into the digital OsteoView 2000 bone densitometer, which is under development at CompuMed and intended for use in detecting osteoporosis and arthritis. In March, CompuMed regained exclusive worldwide rights to the OsteoGram bone density test after licensing them to Merck in 1995 ("The Gray Sheet" Sept. 4, 1995, In Brief). Merck has "invested substantial resources" in the assets related to OsteoGram, CompuMed says, including software enhancements, laboratory equipment, regulatory and clinical work products, intellectual property rights, copyrights, trademarks, marketing materials and artwork, all of which are covered under the agreement...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.